M. Dawson
Molecular Biology · Nature · 2011–2017
A researcher in the Science corpus: 3 papers; trusts 7 researchers and is trusted by 2 researchers here, as inferred from the citation graph.
Subfields
- Molecular Biology — 78 citations into it; #13,686 of 17,773 by trust here, #6,216 by citations
- Hematology — 24 citations into it
- Oncology — 21 citations into it
- Genetics — 13 citations into it
Whom M. Dawson trusts overall
Their strongest outbound trust, strongest first, inferred from their citations.
- P. Park
- M. Vermeulen
- Peter W. Laird
- Keith D. Robertson
- I. Weinstein
- Andrei Krivtsov
- Mathew Garnett
- Skirmantas Kriaucionis
- S. Baylin
- Andrew P. Feinberg
Who trusts M. Dawson overall
Papers from M. Dawson's perspective
Ordered by how strongly the researchers M. Dawson trusts endorse each paper. Same corpus, a different order for every researcher.
- A bivalent chromatin structure marks key developmental genes in embryonic stem cells. (Cell)
- COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
- The Nuclear DNA Base 5-Hydroxymethylcytosine Is Present in Purkinje Neurons and the Brain (Science)
- Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1 (Science)
- Hallmarks of cancer: the next generation. (Cell)
- MLL translocations, histone modifications and leukaemia stem-cell development (Nature Reviews. Cancer)
- Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome (Nature Genetics)
- Suppression of inflammation by a synthetic histone mimic (Nature)
- How chromatin-binding modules interpret histone modifications: lessons from professional pocket pickers (Nature Structural &Molecular Biology)
- Mutation in TET2 in myeloid cancers. (New England Journal of Medicine)
Their papers
- Cancer epigenetics: from mechanism to therapy. (2012) — 3,020 citations
- Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia (2011) — 1,525 citations
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity (2017) — 837 citations